Athersys to Host First Quarter 2014 Financial Results Call
GlobeNewswire - Wed Apr 16, 10:30AM CDT
Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2014 financial results at approximately 4:00 PM (Eastern Time) on Thursday, May 8, 2014, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Stock to Watch: Athersys Down 5.2% (ATHX)
Comtex SmarTrend(R) - Mon Apr 14, 12:45PM CDT
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 5.2% to $2.71 on 1.1x average daily volume. Thus far today, Athersys has traded 1.2 million shares, vs. average volume of 1.1 million shares per day. The stock has underperformed the Dow (-5.2% to the Dow's 0.9%) and underperformed the S&P 500 (-5.2% to the S&P's 0.8%) during today's trading.
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
PR Newswire - Mon Apr 14, 7:16AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Athersys to Present at 2014 BIO Asia International Conference
GlobeNewswire - Wed Mar 26, 1:00PM CDT
Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 2014 BIO Asia International Conference to be held at the Grand Hyatt in Tokyo, Japan, from April 8-9, 2014.
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
MultiStem Overshadows Q4 Loss at Athersys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 2:31PM CDT
Investor focus is more on Athersys' efforts to develop MultiStem than its earnings report.
Hot Stock: Athersys, Shares Drop 6.0% (ATHX)
Comtex SmarTrend(R) - Fri Mar 14, 10:42AM CDT
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 6.0% to $3.46 on 1.0x average daily volume. Thus far today, Athersys has traded 1.3 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's -0.2%) and underperformed the S&P 500 (-6.0% to the S&P's -0.2%) during today's trading.
Athersys Files Shelf Registration Statement to Replace Prior Shelf
GlobeNewswire - Thu Mar 13, 3:23PM CDT
Athersys, Inc. (Nasdaq:ATHX) announced today that it has filed a shelf registration statement with the U.S. Securities and Exchange Commission ("SEC"
Athersys Reports Fourth Quarter and 2013 Annual Results
GlobeNewswire - Thu Mar 13, 3:05PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the fourth quarter and year ended December 31, 2013.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Athersys to Present at Regen Med Investor Day March 26th in New York
GlobeNewswire - Fri Mar 07, 12:15PM CST
Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, Inc. (Nasdaq:ATHX), will present at the second annual Regen Med Investor Day on Wednesday, March 26, 2014 at 1:30 pm (Eastern Time). The conference will be held at the Metropolitan Club in New York City.
Japan's Bold Initiative in Regenerative Medicine and Who the Big Winners Might Be
ACCESSWIRE - Mon Mar 03, 9:55AM CST
Like many other regions in the world, Japan is facing a demographic problem that threatens to pose enormous challenges for their national healthcare system in the years ahead, as the elderly segment of the population expands dramatically. According to analysis by the Ministry of Health Labor and Welfare (MHLW) in Japan, the percentage of the population that is over the age of 65 is expected to nearly double in the coming years. Given that the aging segment of the population requires greater healthcare resources and that this shift will place substantial pressure on the national healthcare system in Japan, it is understandable that the trend has received considerable attention from policy makers.
Athersys to Host Fourth Quarter and Annual Financial Results Call
GlobeNewswire - Tue Feb 25, 9:24AM CST
Athersys, Inc. (Nasdaq:ATHX) will release its 2013 fourth quarter and annual financial results at approximately 4:00 PM EST on Thursday, March 13, 2014, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session